Search

News COVID-19 in Patients with Acquired Hemophilia A −⁠ Case Reports

At the XXVIII. Pařízek Days held in Ostrava, on the afternoon of March 17, 2022, Dr. Anna Maria Pejková from the 4th Internal Clinic of the University Hospital Hradec Králové presented 3 case reports of acquired hemophilia A.

Source: Acquired Hemophilia 29. 3. 2022

Články časopisu Readmission and complication rates in patients undergoing PCNL, stratified by co-morbid factors

Author of the article: N. Ginzburg, A. Ovadiah, D. M. Hoenig Source: Urologické listy | 3/2012 31. 7. 2012

News Early Cytoreductive Treatment Delays Onset of Symptoms Associated with Metastatic Colorectal Carcinoma

Managing symptoms associated with advanced cancer has a significant impact on patients' quality of life and influences decisions about appropriate therapy for an individual patient. An international team of authors conducted a retrospective analysis of 3 clinical trials of the anti-epidermal growth factor receptor (EGFR) antibody panitumumab in the treatment of metastatic colorectal carcinoma (mCRC) and assessed the relationship between tumor response to treatment and the occurrence of symptoms associated with the tumor.

Source: Colorectal Cancer 21. 4. 2020

Články časopisu Proton radiation therapy in the treatment of solid tumours

Author of the article: J. Kubeš, V. Vondráček, J. Abrahámová Source: Praktický lékař | 1/2019 28. 12. 2018

News How to Care for Dialysis Patients in the Times of COVID-19

More than 2 million people worldwide undergo maintenance hemodialysis in outpatient centers. Effective prevention of the spread of infection caused by the SARS-CoV-2 coronavirus within the care provided by hemodialysis centers is essential for the smooth provision of dialysis to patients with end-stage renal disease. The following work from experts in Boston is based on their experiences as well as recommendations from the American Society of Nephrology (ASN) and the Centers for Disease Control and Prevention (CDC).

Source: Chronic Kidney Disease 26. 1. 2021

News Adequate Anti-Xa Levels Are More Often Achieved in Trauma Patients When Dosing Enoxaparin Based on Weight

Thromboembolic disease (TED) is a well-known preventable cause of morbidity and mortality in trauma patients. To improve their prognosis, pharmacological thromboprophylaxis, such as with low molecular weight heparins (LMWH), is an essential part of treatment. However, previously published studies have pointed out that standard dosing of LMWH may be associated with insufficient levels of activity measured using the anti-Xa parameter.

Source: Thromboprophylaxis 3. 3. 2022

News Polatuzumab Vedotin in Combination Treatment of Patients with R/R DLBCL

Polatuzumab Vedotin is a conjugate of a cytostatic agent and an antibody against CD79b, a component of the B-lymphocyte receptor typically expressed by diffuse large B-cell lymphoma (DLBCL) cells. In combination with bendamustine and rituximab (pola-BR), this drug is administered in the 3rd and subsequent lines of treatment for relapsed or refractory (R/R) DLBCL. If allogeneic hematopoietic stem cell transplantation (HSCT) is not feasible, patients with R/R DLBCL generally have a very poor prognosis, with limited further treatment options. However, at the 61st American Society of Hematology (ASH) congress held in December 2019 in Orlando, promising results were presented from extended follow-up of patients treated in clinical studies with the pola-BR combination.

Source: Non-Hodgkin Lymphomas and CLL 3. 2. 2020

News HPD 2024: Bronchitis as an Early Feature of PreCOPD, Role of Mucus Plugs in COPD, and New Findings on Their Exacerbations

Exacerbations of chronic obstructive pulmonary disease (COPD) significantly affect disease progression, quality of life, survival, and cardiovascular events. What to do about them and how to address them most effectively? Why should future treatment also focus more on mucus plugs? And why is it important to consider COPD even in healthy smokers? These topics were discussed by Professor Jadwiga Wedzicha from the National Heart and Lung Institute at Imperial College London during a symposium supported by Angelini at this year's XXVIII Hradec Pulmonary Days.

Source: Cough Therapy 24. 5. 2024

News fSCIG in Elderly Patients with PID or SID in Real Clinical Practice

The work of a team of German and Dutch authors presents data on the real clinical use of 10% subcutaneous immunoglobulin facilitated by hyaluronidase (fSCIG) in elderly patients with primary (PID) or secondary (SID) immunodeficiency.

Source: Primary and Secondary Immunodeficiencies 12. 1. 2023

News Facilitated Immunoglobulin Substitution Therapy in Paediatric Patients with Immunodeficiency –⁠ Real-World Data

Patients with humoral immunodeficiency are indicated for immunoglobulin substitution therapy. The study presented below summarizes real-world data concerning the latest substitution method (i.e., facilitated subcutaneous administration) in paediatric patients.

Source: Primary and Secondary Immunodeficiencies 16. 10. 2023

News Impact of Rehabilitation on the Health of Patients with COPD

According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), pulmonary rehabilitation is one of the most effective therapeutic interventions for reducing dyspnea, improving physical performance, and enhancing quality of life. Below, we summarize current insights on the effectiveness and possibilities of rehabilitation for these patients.

Source: Treatment of Asthma and COPD 15. 11. 2022

News Treatment of COPD in Individuals with Alpha-1 Antitrypsin Deficiency

A mutation in the gene for alpha-1 antitrypsin (AAT), leading to its deficiency (AATD), causes progressive irreversible destruction of lung tissue. Patients develop chronic obstructive pulmonary disease (COPD) and early emphysema. Several studies evaluating COPD treatment have excluded patients with AATD. The aim of the following systematic literature review was to find and analyze works that include patients with concurrent COPD and AATD and summarize key findings that may form the basis for treatment decisions.

Source: Deficiency of Alpha-1-Antitrypsin 6. 12. 2021

News Evaluation of the m7-FLIPI score in patients with follicular lymphoma revealed a promising predictive biomarker for determining suitable chemotherapy

The authors of a study presented at the December congress of the American Society of Hematology (ASH) in Orlando introduced a new prognostic tool, m7-FLIPI, for determining the risk level of patients with follicular lymphoma (FL). They tested its utility using samples from the GALLIUM clinical trial and, during the analysis, discovered a promising biomarker that could help in selecting the primary chemotherapy for FL patients.

Source: Non-Hodgkin Lymphomas and CLL 27. 1. 2020

News Subcutaneous Immunoglobulin Substitution in Ig-Naive Patients with PID –⁠ Available Efficacy and Safety Data

The prevalence of primary immunodeficiencies (PID) is estimated at 1 : 10,000. Below, we summarize the available findings on the efficacy and safety of subcutaneous immunoglobulin substitution in Ig-naive patients (i.e., without prior immunoglobulin substitution).

Source: Primary and Secondary Immunodeficiencies 3. 4. 2023

News Long-term Efficacy, Safety, and Tolerability of Normal Human IgG with Facilitated Absorption in Patients with Humoral Immunodeficiency

The treatment of patients with humoral immunodeficiency is long-term and therefore needs to be not only effective but also safe and well-tolerated. Below, we present the outcomes from an Italian real-world clinical practice study evaluating the efficacy, safety, and tolerability of human immunoglobulin for facilitated subcutaneous administration and patient satisfaction with this therapy.

Source: Primary and Secondary Immunodeficiencies 12. 1. 2023